FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Xeloda news from FiercePharma

News

ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;

> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report > Vanderbilt Medical Read more...

BMS cancer med could earn $500M

Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as Read more...
Tags: Roche   BMS   Ixempra   Bristol-Myers Squibb   Xeloda   FDA  

Get more Xeloda coverage at: